BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating and dose-limiting adverse effect of chemotherapy. Comprehensive self-report tools for CIPN are needed for research and clinical practice. OBJECTIVE: The purpose of this psychometric study was to describe the development and evaluate the reliability and validity of a new self-report tool designed to measure CIPN, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT). METHODS: One hundred sixty-seven patients receiving outpatient chemotherapy with paclitaxel, docetaxel, cisplatin, or oxaliplatin completed the CIPNAT. Content validity, convergent validity, discriminant validity, test-retest reliability, and internal consistency reliability were assessed. RESULTS: Content validity index was very acceptable at 0.95. Convergent validity data were provided by correlation with a measure of the same concept (r = 0.83, P < .001), and differences between contrasting groups (t = 7.66, P < .001) provided evidence of discriminant validity. High test-retest correlations (r = 0.92, P < .001), Cronbach α (α = .95), and significant item-to-total correlations ranging from 0.38 to 0.70 provided evidence of reliability. CONCLUSIONS: Results provide evidence of the validity and reliability of the CIPNAT, which can be used for comprehensive assessment of CIPN. IMPLICATIONS FOR PRACTICE: Use of the CIPNAT in research may lead to a better understanding of CIPN and guide nurses in developing and testing of interventions to relieve suffering and enhance quality of life for patients with CIPN.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) can be a debilitating and dose-limiting adverse effect of chemotherapy. Comprehensive self-report tools for CIPN are needed for research and clinical practice. OBJECTIVE: The purpose of this psychometric study was to describe the development and evaluate the reliability and validity of a new self-report tool designed to measure CIPN, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT). METHODS: One hundred sixty-seven patients receiving outpatient chemotherapy with paclitaxel, docetaxel, cisplatin, or oxaliplatin completed the CIPNAT. Content validity, convergent validity, discriminant validity, test-retest reliability, and internal consistency reliability were assessed. RESULTS: Content validity index was very acceptable at 0.95. Convergent validity data were provided by correlation with a measure of the same concept (r = 0.83, P < .001), and differences between contrasting groups (t = 7.66, P < .001) provided evidence of discriminant validity. High test-retest correlations (r = 0.92, P < .001), Cronbach α (α = .95), and significant item-to-total correlations ranging from 0.38 to 0.70 provided evidence of reliability. CONCLUSIONS: Results provide evidence of the validity and reliability of the CIPNAT, which can be used for comprehensive assessment of CIPN. IMPLICATIONS FOR PRACTICE: Use of the CIPNAT in research may lead to a better understanding of CIPN and guide nurses in developing and testing of interventions to relieve suffering and enhance quality of life for patients with CIPN.
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: J Matt McCrary; David Goldstein; Frances Boyle; Keith Cox; Peter Grimison; Matthew C Kiernan; Arun V Krishnan; Craig R Lewis; Kate Webber; Sally Baron-Hay; Lisa Horvath; Susanna B Park Journal: Support Care Cancer Date: 2017-06-07 Impact factor: 3.603
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Mark Schumacher; Yvette P Conley; Betty Smoot; Gary Abrams; Kord M Kober; Steven Cheung; Jennifer Henderson-Sabes; Margaret Chesney; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: Eur J Oncol Nurs Date: 2017-11-07 Impact factor: 2.398
Authors: Delma Aurélia da Silva Simão; Antônio Lúcio Teixeira; Raissa Silva Souza; Elenice Dias Ribeiro de Paula Lima Journal: Support Care Cancer Date: 2014-05-09 Impact factor: 3.603
Authors: Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman Journal: Muscle Nerve Date: 2016-12-23 Impact factor: 3.217
Authors: Christine Miaskowski; Judy Mastick; Steven M Paul; Gary Abrams; Steven Cheung; Jennifer Henderson Sabes; Kord M Kober; Mark Schumacher; Yvette P Conley; Kimberly Topp; Betty Smoot; Grace Mausisa; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: J Cancer Surviv Date: 2017-11-20 Impact factor: 4.442
Authors: Iva Petrovchich; Kord M Kober; Laura Wagner; Steven M Paul; Gary Abrams; Margaret A Chesney; Kimberly Topp; Betty Smoot; Mark Schumacher; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-04-30 Impact factor: 5.576